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SUMMARY 
Objective: The adamalysin metalloproteinase 15 (ADAM15) has been shown to protect 
against development of osteoarthritis in mice. Here, w  have investigated factors that control 
ADAM15 levels in cartilage.   
Design: Secretomes from wild-type and Adam15-/- chondrocytes were compared by label-free 
quantitative mass spectrometry. mRNA was isolated from murine knee joints, either with or 
without surgical induction of osteoarthritis on male C57BL/6 mice, and the expression of 
Adam15 and other related genes quantified by RT-qPCR. ADAM15 in  human normal and 
osteoarthritic cartilage was investigated similarly and by fluorescent immunohistochemistry. 
Cultured HTB94 chondrosarcoma cells were treated with various anabolic and catabolic 
stimuli, and ADAM15 mRNA and protein levels evaluated.  
Results: There were no significant differences in the secretom s of chondrocytes from WT 
and Adam15-/- cartilage. Expression of ADAM15 was not altered in e ther human or murine 
osteoarthritic cartilage relative to disease-free controls. However, expression of ADAM15 
was markedly reduced upon aging in both species, to the extent that expression in joints of 
18-month-old mice was 45-fold lower than in that 4.5-month-old animals. IL-13 increased 
expression of ADAM15 in HTB94 cells by 2.5-fold, while modulators of senescence and 
autophagy pathways had no effect. Expression of Il13 in the joint was reduced with aging, 
suggesting this cytokine may control ADAM15 levels in the joint.   
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Conclusion: Expression of the chondroprotective metalloproteinase ADAM15 is reduced in 
aging human and murine joints, possibly due to a concomitant reduction in IL-13 expression. 
We thus propose IL-13 as a novel factor contributing to increased osteoarthritis risk upon 
aging.  
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Introduction 1 
 2 
Osteoarthritis (OA) remains the most prevalent of the musculoskeletal diseases, affecting 3 
10% of men and 18% of women over the age of 60, with significant socioeconomic and 4 
healthcare impacts. Age is the major risk factor for development of OA, followed by 5 
obesity and joint injury. There is considerable interest in understanding the molecular 6 
mechanisms by which aging increases OA risk, so that str tegies can be developed to 7 
reduce incidence, halt progression and treat the dis ase. Molecular factors such as 8 
chondrocyte senescence, ‘inflamm-aging’, and oxidative stress increase with age, while 9 
joint biomechanics are altered due to sarcopenia, tendon and ligament damage. These 10 
molecular and mechanical risk factors converge to initiate catabolic signalling pathways 11 
that lead to adaptive and ultimately damaging remodelling of joint tissues. There are also 12 
likely to be additional molecular risk factors that elevate OA susceptibility in aging joints.  13 
Bohm et al.1 showed that adamalysin metalloproteinase 15 (ADAM15) protects 14 
against OA in a mouse model of the disease. Althoug deletion of the enzyme caused no 15 
evident phenotype at birth2, knockout mice developed more severe OA at 12-14 months of 16 
age, in both C57BL/6 and 129/SvJ strains1. Male Adam15-/- mice had 3-fold higher 17 
histological scores than wild-type animals, with females showing a similar trend towards 18 
increased susceptibility with age1. Cartilage fibrillation, fissuring, eburnation and ecrosis 19 
were all higher in Adam15-null mice, along with increased proteoglycan loss, synovial 20 
hyperplasia, and osteophyte formation1.  21 
Metalloproteinases have been widely studied in the context of OA cartilage 22 
degradation, with enzymes such as matrix metalloproteinase (MMP) 13 and adamalysin 23 
with disintegrin and thrombospondin motifs (ADAMTS)-4 and -5 shown to mediate 24 
degradation of type II collagen and aggrecan respectively in murine models of disease. 25 
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Pathological roles have similarly been suggested for many other MMPs and ADAMTSs 26 
which are thought to degrade cartilage matrix components, contribute to bone 27 
remodelling, and participate in cellular signalling pathways.  28 
In contrast with these secreted  metalloproteinases, th  role of transmembrane ADAM 29 
‘sheddases’ in adult joints is less well understood. One of the ADAMs, ADAM15, is of 30 
particular interest as it is the only member of them talloproteinase family shown to 31 
protect against OA. Its mechanism of action remains unclear. The enzyme is thought to be 32 
catalytically active, since as it has an HEXXHXLGXXHD zinc-binding consensus 33 
sequence in its catalytic domain, and cleavage of substrates including E- and N-34 
cadherin3,4, CD445, pro-heparin-binding epidermal growth factor6 and FGF receptor IIIb7 35 
has been described. However, the in vivo relevance of these substrates and of ADAM15’s 36 
catalytic activity to its chondroprotective role have not been tested. The enzyme has been 37 
shown to enhance chondrocyte survival1, possibly by promoting cell-cell3,8,9 and cell-38 
matrix1,3 attachment, and by reducing apoptosis10–12. While the detailed molecular 39 
mechanism underlying these protective effects is not k wn, ADAM15 has been shown to 40 
interact with integrins such as αvβ313 and α5β113, and the cytoplasmic domain of the 41 
enzyme interacts with intracellular signalling molecules such as c-src and focal adhesion 42 
kinase1,11,12,14.  43 
The protective role of ADAM15 is so far not known to extend beyond the joint. Its 44 
expression is elevated in several cancers, and correlates with worse prognosis in some 45 
prostate15, lung16 and breast17 cancers. Loss of Adam15 reduces tumour growth4,18 and 46 
protects against metastasis in murine melanoma19 and bladder4,18 cancer models. 47 
ADAM15 expression is also elevated in the synovial membrane20 and serum21 of 48 
rheumatoid arthritis (RA) patients, and siRNA targeting of ADAM15 reduced arthritis 49 
scores and joint damage in a rat collagen-induced mo el of RA11. Of relevance to both 50 
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cancer and RA, pathological neovascularization is icreased in Adam15-null mice2. Roles 51 
in the vasculature are additionally supported by studies indicating ADAM15 expression in 52 
endothelial cells is increased by sheer stress12 and that it promotes LPS-induced vascular 53 
hyperpermeability22. 54 
Little is known about factors regulating ADAM15 expression. Early studies using in 55 
situ hybridization23 and immunohistochemistry10 indicated that expression of ADAM15 is 56 
increased in OA cartilage, although subsequent microarray studies have reported either no 57 
change or a slight but statistically insignificant i crease in expression in OA (reviewed by 58 
Yang et al.24).  59 
In the current study, we investigated the regulation of ADAM15 in cartilage with 60 
aging and OA, and in response to modulation of pathw ys postulated to increase OA risk 61 
with age. We found that expression of ADAM15 was not altered in OA cartilage, but that 62 
expression of the enzyme reduced markedly with age in both human and murine joints. In 63 
vitro analysis indicated ADAM15 expression was not regulated downstream of senescece 64 
or autophagy, but was increased by IL-13 treatment. mRNA levels of Il13 in the joint 65 
dropped with age, suggesting this cytokine may control ADAM15 expression in the joint 66 
and so be a novel factor contributing to increased osteoarthritis risk upon aging.   67 Jo
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Materials and methods 68 
 69 
Further details are provided in the online Supplementary Materials and Methods file.  70 
 71 
Mass spectrometry analysis of murine chondrocyte secretome 72 
 73 
Chondrocytes were isolated from 6-day-old wild-type (WT) and Adam15-/- mice2 (n=3 74 
animals per group), and  conditioned media analysed by label-free quantitative (LFQ) LC-75 
MS/MS. LFQ was performed only for proteins with at least two ratio counts of unique 76 
peptides. LFQ values were log2 transformed and a two-sided Student’s t-test was used to 77 
evaluate proteins significantly regulated between Adam15-/- and WT chondrocytes. P-78 
values were false discovery rate (FDR)-adjusted to less than 5%. Only proteins detected in 79 
all 3 Adam15-/- and WT samples were statistically analysed.  80 
 81 
Cartilage samples 82 
 83 
Human OA cartilage (n=8 donors, 58-84 years of age) was obtained from donors with 84 
late-stage OA, undergoing unicompartmental knee arthroplasty or total knee arthroplasty 85 
for OA. Human normal cartilage (n=16, aged 9-75 years of age) was purchased from 86 
Articular Engineering (Northbrook, IL, USA) or obtained from Stanmore Biobank (Royal 87 
National Orthopaedic Hospital, Stanmore, UK) from donors undergoing amputation for 88 
low limb malignancies with no involvement of the cartil ge. All cartilage samples were 89 
collected with informed donor consent and in compliance with national and institutional 90 
ethical requirements, the United Kingdom Human Tissue Act, and the Declaration of 91 
Helsinki (HTA Licence 12217 and Oxford REC C 09/H0606/11).  92 
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RNA was isolated from whole knee joints of male C57BL/6 mice (Charles River 93 
Laboratories) with or without surgical destabilisaton of the medial meniscus (DMM) 94 
performed at 10 weeks of age. Sham-operated animals underwent capsulotomy without 95 
destabilisation of the meniscus.  96 
Porcine cartilage explants were dissected from metacarpophalangeal joints of 3-9 97 
month old pigs within 24 h of slaughter. Explants were rested for 3 days in serum-free 98 
cartilage medium (DMEM supplemented with 100 units/ml penicillin, 100 units/ml 99 
streptomycin, 2 mg/ml amphotericin B, 10 mM HEPES) and treated with IL-13 (100 100 
ng/ml) for 48 h. Conditioned media were concentrated by addition of 5% trichloroacetic 101 
acid and analysed by immunoblotting. 102 
 103 
RT-qPCR 104 
 105 
RNA was extracted from cultured cells using RNeasy Mini Kits (Qiagen), and from  106 
human cartilage and whole murine knee joints using TRIzol followed by RNeasy Mini 107 
Kits. After generation of cDNA using High-Capacity cDNA Reverse Transcription Kits 108 
(Thermo Fisher Scientific), qPCR was performed with TaqMan Fast Universal PCR 109 
Master Mix (Thermo Fisher Scientific). Human Taqman primer/probes sets (Thermo 110 
Fisher Scientific) were as follows: ADAM15 Hs00187052_m1, RPLP0 Hs99999902_m1. 111 
Murine Taqman primer/probes sets (Thermo Fisher Scientific, Waltham, MA, USA) were 112 
as follows: Adam15 Mm00477328_m1, Adam17 Mm00456428_m1, Cdkn1a 113 
Mm04205640_g1, Cdkn2a Mm00494449_m1, Il6 Mm00446190_m1, Il13 114 
Mm00434204_m1, Rplp0 Mm00725448_s1, Runx2 Mm00501584_m1, and Sirt1 115 
Mm01168521_m1.  116 
 117 
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Immunofluorescent staining  118 
 119 
Cryosectioned cartilage explants were air dried and fixed in neutral-buffered formalin 120 
and ice-cold acetone. After treatment with chondroitinase ABC, sections were incubated 121 
in blocking buffer (PBS containing 1% goat serum, 5% BSA) and washed in PBS. Primary 122 
antibodies were applied to detect ADAM15 (rabbit anti-ADAM15, Atlas Antibodies, 123 
HPA011633, 2 µg/ml) and/or perlecan (rat anti-perlecan, Millipore). After further washing 124 
in PBS, sections were incubated with appropriate Alxa Fluor-conjugated secondary 125 
antibodies and visualised on an Olympus BX51 fluorescent microscope. Optimal exposure 126 
time for each protein was determined as that giving a signal in positively-stained sections 127 
and no detectable staining in negatively-stained sections, avoiding over-exposure and 128 
signal saturation. Exposure times of individual channels were kept constant. 129 
Quantification was done on raw, unaltered images from at least six random regions using 130 
ImageJ (NIH, Bethesda, MD).  131 
To validate ADAM15 staining, the anti-ADAM15 antibody was pre-incubated with a 132 
10-fold molar excess of recombinant ADAM15, centrifuged, and the supernatant applied 133 
to sections.  134 
 135 
Immunoblotting 136 
 137 
Proteins were separated by SDS-PAGE and transferred to PVDF. Membranes were 138 
incubated (overnight, 4 ℃) with primary antibodies against ADAM15 (rabbit anti-139 
ADAM15, Atlas Antibodies, HPA011633, 0.4 µg/ml) or actin (Abcam, ab3280), washed 140 
in PBS containing 0.2% TWEEN 20, and further incubated with appropriate detection 141 
antibodies for 1 h. After washing as before, signal w s visualised using Clarity Western 142 
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ECL Blotting Substrate (Bio-Rad).  143 
 144 
Statistical analysis 145 
 146 
Statistical tests were performed in GraphPad Prism version 8.4.2 (GraphPad Software, 147 
La Jolla, CA), with all significant changes annotated in figures.  148 
To evaluate whether there was significant variation in the age or sex of cartilage 149 
donors,  groups were tested for normality using the D’Agostino and Pearson omnibus test. 150 
Two-way analysis of variance (ANOVA) was performed, and the forest plots (Fig. 2) were 151 
examined.  152 
RT-qPCR results were analysed using two-tailed Student’s t-tests (to compare between 153 
2 groups), or one-way ANOVA (to compare between more than 2 groups). For the latter, 154 
the derived P values were corrected for multiplicity using Tukey’s test.  155 
For analysis of immunofluorescence images, the background-corrected integrated 156 
intensity values per cell were aggregated for the normal and OA groups (n=3-6 per 157 
group)25, and the  results analysed by one-way ANOVA.   158 
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Results 159 
 160 
The secretome of murine Adam15-/- chondrocytes does not differ significantly from WT 161 
 162 
To investigate potential substrates of ADAM15 in cartil ge, we compared the 163 
abundance of proteins secreted into conditioned media of chondrocytes isolated from 6-164 
day-old WT and Adam15-/- mice using LFQ LC-MS/MS. The analysis identified 108 ECM 165 
proteins (based on Uniprot annotation; Supplemental Table 1), including collagens, 166 
aggrecan, other matrix components and regulators of matrix turnover. The abundance of 167 
these was not altered in the conditioned media of Adam15-/- chondrocytes compared to 168 
their WT counterparts (Fig. 1, Supplementary Table 1). Abundance of the other 1297 169 
proteins analysed was also not altered in Adam15-/- samples. This supports previous 170 
studies indicating Adam15-/- mice have no evident developmental cartilage defects or 171 
phenotype at birth2.   172 
 173 
Expression of ADAM15 is not altered in human OA cartilage 174 
 175 
To evaluate whether expression of ADAM15 was altered in OA cartilage, we analyzed 176 
RNA isolated from cultured chondrocytes and also isolated directly from cartilage of age- 177 
and sex-matched (Fig. 2A) normal (n=12) and OA (n=8) donors. Expression of ADAM15 178 
was about 30% lower in OA chondrocytes than in normal chondrocytes [P=0.0129, 95% 179 
CI (-0.6904, -0.09374), Fig. 2B]. However, there was no significant difference in 180 
ADAM15 expression in mRNA samples isolated directly from cartilage [P=0.7883, 95% 181 
CI (-1.263, 1.64), Fig. 2C]. This indicates that ADAM15 expression is affected by 182 
chondrocyte isolation and in vitro culture, so we sought to analyze RNA isolated directly 183 
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from joint tissues in subsequent analyses. There was also no difference in expression of 184 
ADAM15 in male and female cartilage [P=0.2187, 95% CI (-2.204, 0.5396), Fig. 2D]. 185 
On the other hand, we saw a strong age-dependent varia ion in ADAM15 expression in 186 
cartilage, with low levels of expression in cartilage from young (<20 years of age) and 187 
older (>65 years of age) donors, and highest expression at intermediate ages (Fig. 2E). 188 
Since we had observed no significant difference in expression in OA donors, Fig. 2E 189 
shows data for both normal (closed circles) and OA (open circles) donors.  190 
To evaluate whether ADAM15 is also reduced at the protein level with aging, 191 
immunohistochemistry (IHC) was performed on cryosections of cartilage using a 192 
polyclonal rabbit anti-human ADAM15 antibody. The specificity of the antibody was 193 
evaluated by pre-incubating it with a ten-fold molar excess of recombinant ADAM15 194 
before IHC was performed. This successfully blocked antibody staining (Supplementary 195 
Fig. 1), confirming that the conditions used generated a specific ADAM15 signal. Semi-196 
quantitative evaluation of ADAM15 staining in 6 donors confirmed a trend towards 197 
reduced ADAM15 expression in cartilage with age (Fig. 3). 198 
 199 
Expression of Adam15 is not altered in murine OA cartilage 200 
 201 
We also quantified Adam15 expression in the DMM surgical model of OA, which 202 
recapitulates many of the molecular and pathological features of human OA. There was no 203 
change in Adam15 expression in DMM-operated versus sham-operated knes 6 hours after 204 
joint destabilisation [P=0.4944, 95% CI (-0.2273, 0.1152), Fig. 4A], or 8 weeks 205 
[P=0.4100, 95% CI (-0.1467, 0.9667), Fig. 4B] and 12 weeks after surgery [P=0.1700, 206 
95% CI (-0.2659, 0.6059), Fig. 4B].  207 
 208 
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Expression of Adam15 drops markedly in 18-month old mice 209 
 210 
Changes in Adam15 expression with age were analyzed by isolating RNA from knee 211 
joints of mice aged 0.2-18 months. Expression of Adam15 was readily detectable in all 212 
samples, with Ct values below 20, but expression of the enzyme was significantly lower in 213 
old (18 month) individuals than in younger adults (3, 4.5 and 5.5 months). For example, 214 
Adam15 expression was 45-fold lower at 18 months of age than at 4.5 months [P<0.0001, 215 
95% CI (25.18, 64.48), Fig. 4C]. 216 
Age-dependent expression of a range of other genes was also examined in these 217 
samples. Expression of Adam17, a related metalloproteinase, was also higher at 4.5 218 
months than at 18 months, but only by 2-fold [P=0.0012, 95% CI (0.2944, 1.478), Fig. 219 
4D]. Similarly, expression of Sirt1 and Runx2 were 1.3-fold higher [P=0.0851, 95% CI (-220 
0.1153, 0.2604), Fig. 4E] and 0.8-fold higher [P=0.0003, 95% CI (0.3250, 1.263), Fig. 221 
4F], respectively, in 4.5-month-old mice compared with 18-month-old mice. No age-222 
dependent variation in Cdkn1a (Fig. 4G) was observed, but expression of and Cdkn2a 223 
(Fig. 4H) and Il6 (Fig. 4I) increased with age.  224 
 225 
IL-13 stimulates expression of ADAM15 in human HTB94 chondrosarcoma cells 226 
 227 
In an attempt to understand what may drive the age-dependent changes in ADAM15 228 
expression observed, we screened a number of candidate regulators suggested to regulate 229 
ADAM15 in other cell types, or with possible relevance to OA, aging or inflammation 230 
using a human cell culture model.  231 
Dihydrotestosterone (DHT) has been shown to increase ADAM15 expression in MCF-232 
7 breast cancer cells, while estradiol had no effect26. Neither hormone had any effect on 233 
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ADAM15 expression in HTB94 chondrosarcoma cells (Fig. 5A). Mirin, a small molecule 234 
inducer of senescence27–29, suppressed ADAM15 expression after 24 hours of treatment 235 
[P=0.0298, 95% CI (-0.6994, -0.06061), Fig. 5A], but this effect was not observed at 48 236 
hours and mirin had no effect on protein levels of ADAM15. No effect was seen with the 237 
SIRT1 activator resveratrol or the SIRT1 small molecu  inhibitor EX-527.  Similarly, 3-238 
methyladenine (3-MA), which inhibits autophagosome formation by inhibiting 239 
phosphatidylinositol 3-kinase (PI3K), had no effect on ADAM15 expression.  240 
Among the cytokines and inflammatory mediators tested, GM-CSF [P=0.0009, 95% 241 
CI (3.256, 0.6236), Fig. 5B] and IL-13 [P=0.0047, 95% CI (3.016, 0.3836), Fig. 5B] both 242 
stimulated ADAM15 expression. No effect was seen with the other cytokines (M-CSF, 243 
TNF, IFNγ, IL-1, IL-4, IL-6, IL-10), growth factors (activin, BMP-7, CTGF, FGF2, 244 
FGF18, TGFβ) or inflammatory mediators (dexamethasone, PMA, retinoic acid, LPS) 245 
tested (Fig. 5A, B). 246 
Treatment of HTB94 chondrosarcoma cells with 100 ng/ml IL-13 for 48 h also 247 
increased levels of ADAM15 by 2.5-fold at the protein level [P=0.0017, 95% CI (08426, 248 
2.691), Fig. 5C]. IL-13 similarly stimulated expression of ADAM15 in primary porcine 249 
cartilage explants [P=0.0105, 95% CI (2.528, 0.6091), Suppl. Fig. 2]. 250 
To investigate whether IL-13 may contribute to the ag -dependent changes in Adam15 251 
expression in the joint, we measured Il13 expression in the samples used in Fig. 4.  This 252 
showed that Il13 expression was reduced by 75% in joints from 18-month- ld mice 253 
compared with 4.5-month old animals [P=0.0062, 95% CI (0.903, 6.953), Fig. 5E].  254 
Expression of Adam15 in individual animals correlated with their expression of Il13 255 
(Suppl. Fig. 3, R2 = 0.7538).  256 
 257 
Discussion 258 
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 259 
Metalloproteinases have been extensively studied as mediators of cartilage degradation in 260 
OA, with enzymes such as MMP-13 and ADAMTS-5 thought to be of particular 261 
importance in degrading the cartilage extracellular m trix and promoting structural failure 262 
of joints. As a result, these enzymes have been the targ t of pharmaceutical and academic 263 
OA drug discovery programmes. Metalloproteinases were similarly extensively studied in 264 
the context of cancer, but translational development of metalloproteinase inhibitors failed 265 
in this field, due in part to high homology between the metalloproteinase catalytic 266 
domains, which caused off-target inhibition of metalloproteinases with homeostatic roles. 267 
This cross-reactivity is also likely to be important in the development of 268 
metalloproteinase-targeted OA therapies, in particular due to the chronic nature of OA and 269 
the high incidence of co-morbidities in aging OA patients. It is thus of considerable 270 
importance to identify metalloproteinases that have protective or homeostatic functions in 271 
the joint, and to establish the timing, location and regulation of their activities. 272 
ADAM15 is the first metalloproteinase shown to protect against OA in adult murine 273 
joints, with Adam15-/- mice exhibiting higher levels of spontaneous OA at 12-14 months 274 
of age1. The mice have no evident developmental defects2, and we observed no difference 275 
in secretion of extracellular matrix molecules by chondrocytes isolated from young 276 
animals. These data indicate the enzyme serves its pro ective function primarily in adult 277 
cartilage.  278 
Using RNA extracted directly from normal and OA human knee cartilage, we found 279 
that expression of ADAM15 was not increased in OA samples relative to age-matched 280 
controls. Similarly, we saw no regulation of Adam15 in the DMM surgical model of 281 
murine OA, either in the hours immediately after surgery or at the time of joint damage (8- 282 
and 12-weeks after surgery). These findings are in agreement with several microarray 283 
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studies, as previously reviewed by Yang et al.24.  284 
In contrast, we saw strong down-regulation of ADAM15 with age. In both human and 285 
murine samples, expression of ADAM15 was highest in adult joints, with lower 286 
expression in young and old donors. This bell-shaped expression profile further supports 287 
the conclusion that ADAM15 functions largely in adult tissues, and is required for 288 
cartilage maintenance rather than development. Thisexpression pattern did not reflect 289 
global changes in expression with age, since minimal changes were observed in 290 
expression of the related metalloproteinase Adam17 or the transcription factor Runx2, for 291 
example. Expression of the senescence markers Il630 and Cdkn2a31,32 but not Cdkn1a31,32  292 
also increased in murine joints with age, in line with previous reports. We did not observe 293 
the previously reported aging-dependent decrease in expression of the histone deacetylase 294 
Sirt1, although this reduction has largely been reported at the protein level33,34, possibly 295 
reflecting post-translational regulation. Based on the increase in Il6 and Cdkn2a, we 296 
conclude that the decrease in Adam15 expression occurs when joints showed cellular and 297 
biochemical signs of aging.  298 
Given its apparent protective role in the joint, were keen to explore what factors 299 
could drive expression of ADAM15 and underlie its reduced expression with aging. Mirin, 300 
a chemical inducer of cellular senescence, transiently reduced ADAM15 mRNA levels in 301 
HTB94 chondrosarcoma, but had no effect on protein levels or on mRNA expression after 302 
24 hours. Modulators of SIRT1 (resveratrol and EX-527) and autophagy (3-MA) had no 303 
effect on ADAM15 expression. Similarly, factors previously shown to stimulate small (2-304 
4-fold) increases in ADAM15 expression in cancer cells and RA synovial fibroblasts (i.e. 305 
dihydrotestosterone26, LPS11) were ineffective in HTB94 chondrosarcoma cells, as were a 306 
range of other pro- and anti-inflammatory stimuli.  307 
However, we saw a 3-fold increase in ADAM15 expression upon treatment with GM-308 
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CSF and IL-13. GM-CSF may be of importance in immune contexts, but we considered 309 
IL-13 more likely to have a role in the joint, since it has been previously been shown to 310 
block collagen release from IL-1/oncostatin M-stimulated bovine nasal cartilage in vitro, 311 
potentially via suppressing MMP3 and MMP13 expression35. Broader suppressive effects 312 
on inflammatory signalling in OA36 and RA synovial explants37,38 and in vivo murine RA 313 
models39–41 have also been reported.  314 
IL-13 can bind either to the type I IL-13 receptor (a dimer of the IL-13 Receptor, 315 
IL13R, and the IL1-4 Receptor, IL4R) or to the decoy type II IL-13 receptor (a dimer of 316 
the IL13R). Both the IL13R and IL4R are expressed in cartilage, with no change in 317 
expression reported in OA42. IL-4 has been shown to block metalloproteinase expression42 318 
and matrix breakdown43 in cytokine-stimulated OA cartilage explants, and polymorphisms 319 
in IL4 and IL4R have been associated with OA44,45, supporting a potential role for this 320 
signalling pathway in joint homeostasis. To our knowledge, this is the first report showing 321 
a reduction in Il13 expression in murine joints upon aging. Spadaro et al. found that IL-13 322 
levels were higher in the synovial fluid of patients with inflammatory (rheumatoid and 323 
psoriatic) arthritis than those with OA46, but direct comparison between OA and healthy 324 
synovial fluid was not reported.  Analysis of OA susceptibility in Il13-/- mice would shed 325 
light on the role of this cytokine in the joint environment.   326 
Recent studies have indicated that ADAM15 expression is increased by sheer stress in 327 
endothelial cells12 and by scratch wounding of cultured glomerular mesangial cells47. 328 
ADAM15 expression may thus be regulated by mechanical stimuli, which would be of 329 
considerable importance in cartilage, although the absence of Adam15 regulation in the 330 
DMM model argues against this possibility.  Activity of ADAM17 can be mechanically 331 
stimulated through c-Src mediated signalling pathways48, raising the possibility that joint 332 
biomechanics could alter ADAM15 activity as well asexpression. ADAM15 has low 333 
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sensitivity to tissue inhibitor of metalloproteinases 3 (TIMP-3)49, the physiological 334 
inhibitor of most ADAMs, supporting the possibility hat access to its active site may be 335 
conformationally regulated. Changes in joint mechanics change with age may synergise 336 
with changes in cytokine profile to effect significant changes in ADAM15 expression and 337 
activity in the joint.  338 
The molecular mechanism(s) by which ADAM15 protects artilage remain unclear. 339 
Our proteomic analysis did not identify any novel AD M15 substrates in chondrocytes, in 340 
line with previous limited identification of ADAM15 substrates in other cell types. This 341 
indicates that the enzyme either has high substrate specificity, requires activation through 342 
as yet unknown mechanisms, and/or serves its protective function by mechanism(s) other 343 
than proteolytic shedding. Cleavage of soluble and not membrane-bound substrates, for 344 
example, would require different proteomic approaches for identification. Alternatively, 345 
ADAM15 effects in cartilage may be independent of proteolytic activity, as has been 346 
shown for its effects on pathological retinal neovascularisation50.   347 
The roles of many other ADAM and ADAMTS metalloproteinases in adult cartilage 348 
and joints have also not yet been established. Many of these show strong regulation in 349 
OA24, and given their participation in cell signalling and survival pathways, it is likely that 350 
at least some of these enzymes contribute to joint homeostasis. Further investigation of 351 
their activities will strengthen our ability to target dysregulated matrix turnover in OA.  352 
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Fig. 1. Secretome of Adam15-/- chondrocytes is not significantly different from WT.     1 
(A) Volcano plot showing the −log10 of P-values versus the log2 of protein abundance in 2 
media of Adam15-/- versus WT chondrocytes (n=3 animals per group). The hyperbolic 3 
curves represent a permutation-based FDR correction for multiple hypotheses (P = 0.05, 4 
s0 = 0.1). Detected proteins were below the curve aft r FDR, and thus were not 5 
significantly different between the groups. ECM proteins (based on Uniprot annotation) 6 
are shown in blue. (B) Abundance of collagens and aggrecan were not altered in the media 7 
of Adam15-/- chondrocytes compared to WT. (C) Abundance of other selected extracellular 8 
matrix components and regulators was also not altered in the medium of Adam15-/- 9 
chondrocytes. 10 
 11 
Fig. 2. Expression of ADAM15 is not altered in human OA cartilage, but is reduced 12 
with age.  13 
(A) Forest plot showing that donors used for (B-D) were age- and sex-matched. Mean age 14 
for all samples was calculated and subtracted from the mean age of OA females (n = 5), 15 
OA males (n = 3), normal females (n = 6) and normal es (n = 6). Data are depicted as 16 
differences in means (ΔMean) with 95% CI. ΔMeans were not significantly different (P = 17 
0.7886). (B) Chondrocytes were isolated from normal (n = 12, 58-75 years of age) and OA 18 
(n = 8, 58-84 years of age) cartilage and cells cultured in monolayer for 5 days. RNA was 19 
isolated and expression of ADAM15 quantified by RT-qPCR, relative to RPLP0 and to 20 
mean expression in normal chondrocytes (mean ± SD). (C) RNA was extracted from 21 
normal (n = 12, 58-75 years of age) and OA (n = 8, 58-84 years of age) cartilage samples 22 
matching those in (B), and expression of ADAM15 quantified by RT-qPCR, relative to 23 
RPLP0 and to mean expression in normal cartilage (mean ± SD). (D) Data shown in (C) 24 
were analysed by gender, irrespective of OA status, with expression normalised to the 25 
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mean of expression in female donors (mean ± SD). (E) Data shown in (C), along with data 26 
from an additional 4 normal donors (9-16 years of age), were analysed by age. Samples 27 
from normal cartilage are shown in closed circles (n = 16) and those from OA cartilage 28 
shown in open circles (n = 8). * P < 0.05,  ***P < 0.001.  29 
 30 
Fig. 3. Cartilage expression of ADAM15 also decreases with age at the protein level.  31 
(A) Cartilage sections from donors aged 47, 54 and 90 were stained with anibodies 32 
against ADAM15 (red) and perlecan (green), and counterstained with DAPI. Exposure 33 
times for each channel were kept constant for all samples. (B) Expression of ADAM15 34 
was semi-quantitatively evaluated in 3 normal (red) and 3 OA (orange) donors of various 35 
ages, with each dot representing integrated fluorescence intensity per single cell, 36 
calculated from at least six random fields of view on three sections per donor. Median 37 
fluorescence intensity with 95% CIs of the mean are shown.  38 
   39 
Fig. 4. Expression of Adam15 is reduced with age in murine joints. (A) RNA was 40 
extracted from joints of male mice 6 hours after DMM or sham surgery and expression of 41 
Adam15 quantified by RT-qPCR, relative to Rplp0 and average expression in sham-42 
operated joints (mean ± SD, n = 8 animals per group). (B) RNA was extracted from joints 43 
of male mice 8 and 12 weeks after DMM or sham surgery or from age-matched naïve 44 
controls, and expression of Adam15 quantified by RT-qPCR, relative to Rplp0 and average 45 
expression in naïve joints (mean ± SD, n = 5-13 anim ls per group). (C-I) RNA was 46 
extracted from joints of male mice aged 0.2 to 18 months as indicated, and expression of 47 
Adam15 (C), Adam17 (D), Sirt1 (E), Runx2 (F), Cdkn1a (G), Cdkn2a (H) and Il6 (I) were 48 
quantified by RT-qPCR, relative to Rplp0 (mean ± SD, n = 6-13 animals per group). Data 49 
are expressed relative to average expression in 18-month old mice (C) or 0.2 month old 50 
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mice (D-I).  * P ≤ 0.05,  ** P ≤ 0.01, ****, P ≤ 0.0001. 51 
 52 
Fig. 5. IL-13 stimulates expression of ADAM15. 53 
(A) After 24 h of serum starvation, HTB94 cells were tra ed for a further 24 h with 54 
Dexamethasone (1 µM, DMSO control), phorbol 12-myristate 13-acetate (DMSO 55 
control), dihydrotestosterone (DHT, 0.1 µM, methanol control), estradiol (0.1 µM, ethanol 56 
control), mirin (50 µM, DMSO control), resveratrol (10, 50, 100 µM, ethanol control), 57 
EX-527 (1, 10 µM, DMSO control) or 3-MA (5 µM, DMSO control). RNA was extracted 58 
and expression of ADAM15 quantified by RT-qPCR, relative to RPLP0 and mean 59 
expression the respective controls (mean ± SD, n = 3). (B) After 24 h of serum starvation, 60 
HTB94 cells were treated for a further 24 h with M-CSF (100 ng/ml), GM-CSF (50 61 
ng/ml), TNF (100 ng/ml), IFNγ (100 ng/ml), IL-4 (20 ng/ml), IL-6 (20 ng/ml), IL-10 (10 62 
ng/ml), IL-13 (20 ng/ml), LPS (100 ng/ml), activin A (50 ng/ml), BMP-7 (100 ng/ml), 63 
CTGF (100 ng/ml), FGF2 (100 ng/ml), FGF18 (100 ng/ml) or TGFβ (10, 100 and 1000 64 
pg/ml), for 24 h. RNA was extracted and expression of ADAM15 quantified by RT-qPCR, 65 
relative to RPLP0 and the average expression in control (left panel) or DMSO-treated 66 
(right panel) cells (mean ± SD, n = 3). (C) After 24 h of serum starvation, HTB94 cells 67 
were treated with IL-13 (100 ng/ml) for 48 h, cells lysed in SDS sample buffer, and 68 
expression of ADAM15 and actin analysed by immunoblotting.  (D) Band intensities from 69 
(B) were quantified and expression of ADAM15 normalised to actin plotted (mean ± SD, 70 
n = 6). Arrow indicates predicted position of active ADAM15. (E) RNA was extracted 71 
from joints of male mice aged 0.2 to 18 months as indicated, and expression of Il13 72 
quantified by RT-qPCR, relative to Rplp0 and to average expression in 18-month old mice 73 
(mean ± SD, n = 6-13). * P < 0.05, **P < 0.01. 74 
 75 
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Supplementary Fig. 1. Validation of anti-ADAM15 antibody specificity by antigen 76 
blocking. Cryo-sections of OA cartilage were stained with antibodies against ADAM15 77 
(red) and perlecan (green), and counterstained with DAPI. In right hand panels, the anti-78 
ADAM15 antibody was pre-incubated with a 10-fold molar excess of recombinant 79 
ADAM15 in PBS for 30 minutes at room temperature. The antigen-antibody mixture was 80 
centrifuged (15 min, 17000 x g) and the supernatant applied to tissue sections. Images 81 
were taken using the same exposure times.  82 
 83 
Supplementary Fig. 2. IL-13 stimulates expression of ADAM15 in porcine cartilage 84 
explants. Porcine cartilage explants were treated with IL-13 ( 00 ng/ml) for 48 h in 85 
serum-free DMEM, and conditioned media concentrated by addition of 5% trichloroacetic 86 
acid. Samples were analysed for ADAM15 expression by immunoblotting, and band 87 
intensities quantified (mean ± SD, n=3 technical rep icates per group). * P < 0.05 88 
 89 
Supplementary Fig. 3. Correlation between expression of Adam15 and Il13 in murine 90 
joints. RNA was extracted from joints of male mice (aged 0.2, 3, 4.5, 5.5 and 18 months, 91 
n = 6-13 animals per age group) and expression of Adam15 and Il13 quantified by RT-92 
qPCR, relative to Rplp0. ∆Ct values for Adam15 expression in each animal were plotted 93 
against their ∆Ct values for Il13. Data were normally distributed and had a Pearson’s 94 
correlation coefficient of 0.7538.  95 
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